IceCure Medical Business Summary

IceCure Medical Ltd. (ICCM) is a commercial-stage medical device company that generates revenue through the sale of its proprietary ProSense cryoablation systems and high-margin, single-use disposable cryoprobes. The company operates primarily within the interventional oncology segment, utilizing liquid nitrogen (LN2) technology to destroy benign and malignant tumors—including those in the breast, kidney, lung, and bone—via extreme cold. Following a landmark October 2025 FDA marketing authorization for the treatment of low-risk, early-stage breast cancer in women aged 70 and older, IceCure has pivoted toward a high-growth commercial model in the United States, supported by established CPT III reimbursement codes. Its direct competitors include AngioDynamics, Sanarus, and Varian Medical Systems (specifically its Galil Medical and Endocare product lines); IceCure distinguishes itself as a leader in LN2-based systems, offering a faster, office-based alternative to traditional surgical resection and argon-based cryoablation technologies. The company was founded in 2006 by Didier Toubia, a serial entrepreneur also known for founding Aleph Farms. The leadership team is headed by CEO Eyal Shamir, who brings extensive experience from Hanita Lenses and B-Cure Laser, and CTO Naum Muchnik, who leads the research and development of the next-generation XSense and MultiSense platforms. In late 2025, the executive suite was strengthened by the appointment of Shay Levav as Chief Operating Officer, while long-time CFO Ronen Tsimerman announced his planned departure in February 2026, remaining in his role to oversee the transition to a successor. The Board of Directors is chaired by Ron Mayron, former CEO of Teva Israel, and the company maintains a strong institutional backing from notable investors including Samena Capital and Epoch Partner Investments Ltd.